Rona Therapeutics Secures RMB 250 Million (USD 35 Million) in Series A+ Financing to Advance Global siRNA Pipeline and Expand Extrahepatic Delivery Platforms

Jul 20, 2024 10:48 CST Updated 10:48

Rona Therapeutics

Nucleic Acid Drug Developer

NEWS

➤ Financing was led by LongRiver Jiangyuan Investment, with participation from existing shareholders and global capital.

➤ Rona Therapeutics will use the proceeds to advance its leading siRNA metabolic pipeline projects into global development and expand its extrahepatic delivery platform for the central nervous system and other fields.

On July 19, 2024, Rona Therapeutics (Shanghai) Co., Ltd. ("Rona Therapeutics") officially announced the successful completion of a US$35 million (approximately RMB 250 million) Series A+ financing round.This round of financing was led by LongRiver Jiangyuan Investment, with participating investors including Zhaode Investment, Boyuan Capital, Zhongqi Capital, and Lilly Asia Ventures, among others.

LongRiver Jiangyuan Investment, as the leading investor in the A+ round, will join the board of directors of Rona Therapeutics and has highly praised the company's innovative capabilities and market prospects in the field of nucleic acid drug research and development. LongRiver Jiangyuan Investment stated: "Rona Therapeutics has successfully brought two best-in-class siRNA metabolism projects into global development, demonstrating differentiated clinical data and platform value. We are deeply impressed by Rona Therapeutics' progress in developing an innovative siRNA pipeline and expanding into CNS and other extrahepatic delivery. We look forward to collaborating with the Rona Therapeutics team to unlock the potential of RNA drugs as transformative therapies for the benefit of patients worldwide."

CEO of Rona Therapeutics

Co-Founder

Stella SHI

We warmly welcome Jangfar Investment and other new shareholders. Rona Therapeutics is committed to advancing more best-in-class and first-in-class siRNA projects into global clinical trials while promoting further potential business development opportunities. Leveraging our proprietary RNA platform, we will strive to push boundaries and fully drive the research and development of RNA drugs in the areas of metabolism, obesity, renal diseases, and neurodegenerative disorders.

Rona Therapeutics is advancing a pipeline of best-in-class and first-in-class siRNA programs based on a next-generation siRNA platform.Rona Therapeutics' first pipeline, RN0191, as the best-in-class PCSK9 siRNA project, has completed Phase I clinical studies in Australia and China, and is actively advancing into Phase II clinical development for hypercholesterolemia. RN0361, the company’s second pipeline targeting the treatment of hypertriglyceridemia, entered clinical trials in the second quarter of 2024. Rona Therapeutics is also concurrently advancing preclinical stage experiments for innovative pipelines aimed at treating kidney diseases, obesity, and cardiometabolic disorders.

About Rona Therapeutics

Rona Therapeutics is a globally leading nucleic acid innovative drug platform company, focusing on the treatment of metabolic diseases and central nervous system degenerative diseases. Rona Therapeutics is committed to developing best-in-class siRNA drugs, demonstrating unique differentiation and innovation in cardiovascular diseases, non-alcoholic fatty liver disease, obesity, and kidney diseases within its liver-targeted metabolic pipeline. Additionally, Rona Therapeutics explores the potential of extrahepatic nucleic acid delivery in central nervous system degenerative diseases, successfully establishing its proprietary extrahepatic delivery platform aimed at treating complex diseases such as amyotrophic lateral sclerosis and Alzheimer's disease, which are challenging for traditional drug therapies.

About LongRiver Jiangyuan Investment

LongRiver Investments focuses on investments in the medical and technology sectors, aiming to support enterprise development, connect industry resources, and share long-term returns. Over the past decade, the team has raised multiple USD and RMB funds, investing in more than 50 medical and technology companies globally, nearly 20 of which have been listed on exchanges in and outside of China. The first phase of LongRiver Investments' fund reached nearly 4 billion USD in size, with investors including multinational financial institutions and top-tier asset management companies as long-term investors. The team has strategically focused on areas such as healthcare, new energy and materials, and advanced manufacturing, covering investment stages from early to later phases. Leveraging its international perspective, long-term funds, and specialized expertise, the team has established comprehensive capabilities in "sourcing deals, conducting due diligence, providing value-added support, and exiting successfully." In the future, LongRiver Investments will continue to focus on the technology sector, bridging new drivers of global industrial development, and supporting and nurturing the next generation of industry leaders.

E.N.D

Previous article recommendations:

Gene-editing therapy cures first foreign patient, 18-year-old girl gets a new life

Cell Therapy Start-up Xiatong Biotech Secures Investment from Well-Known Listed Company's Fund

OEBio Releases "Process Characterization and Process Validation Manual (Cell and Gene Therapy)"

First in China's biomanufacturing field! A national-level industrial center begins construction, focusing on technology platforms for large-scale viral vector preparation and quality control, as well as drug GMP production.

Clinical-Grade "0 Off-Target" Gene Editor AaCas12bMax Helps Improve the Accessibility of Therapeutic Gene Editing Therapies

Hengrui Medicine Subsidiary’s AAV Dual-Gene Drug IND in China Accepted for Review

Total investment of nearly 10 billion yuan! Focusing on the cell industry, the first batch of projects in a biomedicine city in China has started construction.

Cai Lei Donates to Support ALS Research at Westlake University

First in China! SIRLING Bio Non-Gene-Edited Universal NK Cell Therapy Approved for Clinical Trials

Shanghai Makes a Big Move by Establishing a 21.5 Billion Biomedical Industry Guidance Fund!

Haobo Medicine Completes RMB 260 Million Series A Financing

Baiji Bio's Solid Tumor CAR-T Cell Therapy Enters Pivotal Phase II Clinical Trial

Precise Delivery of Gene Drugs into the Brain: Positive Progress for Parkinson's Disease AAV Gene Therapy

China's National Medical Products Administration Food and Drug Verification Center Releases "Guidelines for On-site Inspection of Cell Therapy Product Manufacturing (Draft for Comments)"

Innovative Gene Therapy Class 1 Drug Submitted for Market Approval, Developed by Rona Therapeutics!

Received Acquisition Offer, Legend Biotech Surges 12%

Registered capital of 100 million yuan, focusing on cell therapy, a cell technology company officially opens in China

Shanghai Municipal Medical Products Administration Releases "Shanghai Municipality's Autologous Chimeric Antigen Receptor T-Cell (CAR-T) Supervision and Management Regulations (Draft for Public Comment)"

Rona Therapeutics Secures Additional Tens of Millions in A+ Round Financing

Hengrui Medicine's Subsidiary Completes First Human Dosing of Self-Developed AAV Dual-Gene Drug

CSPC RSV mRNA Vaccine in ChinaApproved for Clinical Use

Total investment of 120 million yuan, building area of 14,000 square meters, another commercial production base for cell therapy products in China officially launched.

Milestone! In Vivo CAR-T Therapy Approved for Clinical Trials for the First Time

"Ethical Guidelines for Human Genome Editing Research" Released!

Chinese Team Develops Full-RNA Mediated Large-Fragment Gene Efficient and Precise Targeted Integration Technology, Boosting the Development of a New Generation of Innovative Gene Therapies

Review of 40 Global Stem Cell Therapy Companies and Their Technology Pipelines

China's Cell Therapy Clinical Trials Reach 385, Cell Therapy Industry Booms

Innovent Biologics Invests in Icarus Bio, Deepening Strategic Cooperation

CDE Releases "Nonclinical Research Technical Guidelines for Adeno-Associated Virus Vector Gene Therapy Products (Draft for Comments)"

Over 10 billion yuan investment! Beijing introduces hard-core measures, multi-factor support for cell and gene therapy, artificial intelligence and other high-end industries

A Gene Therapy Company in Hangzhou Officially Opens

Disclaimer: The content is sourced from Rona Therapeutics' official channels. This article aims to share knowledge, and all content is for reference only and does not constitute any advice.。